EU and US could reach trade deal this weekend - Reuters
Immuneering Corporation (NASDAQ:IMRX), a pharmaceutical preparations company, reported on Monday the results of its Annual Meeting of Stockholders held on June 13, 2025. The meeting saw the election of three Class I directors and the ratification of the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
The stockholders present in person or by proxy represented approximately 69.1% of the outstanding Class A common stock as of the April 17, 2025, record date. The definitive proxy statement detailing the meeting’s agenda was filed with the SEC on April 21, 2025. Want deeper insights into Immuneering’s governance and financial metrics? InvestingPro offers 11 additional exclusive tips and comprehensive analysis for informed investment decisions.
The election results for the three Class I director positions were as follows: Ann E. Berman received 13,230,831 votes for, none against, and 1,625,960 withheld; Diana F. Hausman, M.D. garnered 13,564,145 votes for, none against, and 1,292,646 withheld; and Thomas J. Schall, Ph.D. obtained 14,630,652 votes for, none against, and 226,139 withheld. All three nominees have been elected to serve until the 2028 Annual Meeting of Stockholders.
Additionally, the appointment of RSM US LLP as the company’s independent registered public accounting firm was ratified with 24,648,142 votes for, 191,884 against, and 26,404 abstentions.
Immuneering Corp, based in Cambridge, Massachusetts, is incorporated in Delaware and specializes in the pharmaceutical preparations industry. While the company maintains a strong financial position with more cash than debt and a healthy current ratio of 7.48, investors should note it is currently unprofitable and burning through cash reserves. The company’s Class A common stock is listed on The Nasdaq Global Market under the trading symbol IMRX. This report is based on the 8-K filing submitted to the Securities and Exchange Commission.
In other recent news, Immuneering Corporation has appointed Dr. Igor Matushansky as its new Chief Medical (TASE:BLWV) Officer. Dr. Matushansky will lead the clinical strategies for the company’s cancer drug programs, including the ongoing Phase 2a trial of IMM-1-104, which is being developed for treating pancreatic cancer. The appointment is timely as Immuneering plans to present updated data from this trial in the second quarter of 2025. Dr. Matushansky brings extensive experience in oncology, having previously held significant roles at Sail Biomedicines and Ipsen (EPA:IPN) Pharmaceuticals, among others. He has been involved in the approval of treatments like NALIRIFOX for pancreatic cancer, highlighting his expertise in this field. Immuneering’s CEO, Ben Zeskind, emphasized Dr. Matushansky’s understanding of the patient experience as a key asset for the company. The company’s pipeline includes IMM-1-104 and IMM-6-415, both MEK inhibitors targeting RAS-driven tumors and advanced solid tumors, respectively. Dr. Matushansky expressed enthusiasm for joining the team and collaborating on the ongoing and future trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.